Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclic progesterone plus spironolactone for androgenic PCOS
ISRCTN99343883Phase 2Completed
- Sponsor
- Women's Health Research Institute
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of progesterone and spironolactone in polycystic ovary syndrome (PCOS), sponsored by Women's Health Research Institute. Primary endpoint: Health-related quality of life by PCOS-Q. Started Oct 2021; status: completed.
02
Drugs
progesteronespironolactone
03
Conditions
polycystic ovary syndrome (PCOS)
Beyond the preview
Go deeper on ISRCTN99343883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN99343883.